Question

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

5 comments5

Total Forecasters36

Community Prediction59.7% (50% - 63%)

Make a Prediction

50%

community: 59.7%

Authors:

casens

Opened:

Nov 24, 2021

Closes:

Jan 1, 2029

Scheduled resolution:

Jan 1, 2029

Health & Pandemics

Food and Drug Administration

The Health Risks and Benefits of Weight-Loss Drugs

Time•Jan 21, 2025

The Conversation•Jan 23, 2025

As weight loss drug demand soars, physician outlines effectiveness and potential downsides

PBS NewsHour•Jan 26, 2025

Learn more about Metaculus NewsMatch

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

80.8%

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

43%

Comments

? comments

Authors:

casens

Opened:

Nov 24, 2021

Closes:

Jan 1, 2029

Scheduled resolution:

Jan 1, 2029

Health & Pandemics

Food and Drug Administration

The Health Risks and Benefits of Weight-Loss Drugs

Time•Jan 21, 2025

The Conversation•Jan 23, 2025

As weight loss drug demand soars, physician outlines effectiveness and potential downsides

PBS NewsHour•Jan 26, 2025

Learn more about Metaculus NewsMatch

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

80.8%

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

43%